These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1622 related items for PubMed ID: 8473405

  • 1. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 2. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.
    Regul Pept; 1994 Apr 14; 51(1):63-74. PubMed ID: 8036284
    [Abstract] [Full Text] [Related]

  • 3. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    Digestion; 1992 Apr 14; 52(3-4):214-21. PubMed ID: 1459356
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G, Thomaseth K, Ahrén B.
    Metabolism; 2010 Jul 14; 59(7):988-92. PubMed ID: 20153002
    [Abstract] [Full Text] [Related]

  • 9. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.
    Regul Pept; 2004 Nov 15; 122(3):209-17. PubMed ID: 15491793
    [Abstract] [Full Text] [Related]

  • 10. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan 15; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 11. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA, Siemsglüss J, Orskov C, Holst JJ.
    Z Gastroenterol; 1996 Mar 15; 34(3):159-66. PubMed ID: 8650968
    [Abstract] [Full Text] [Related]

  • 12. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct 15; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 13. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 15; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.
    Diabetes; 2005 Jul 15; 54(7):2212-8. PubMed ID: 15983224
    [Abstract] [Full Text] [Related]

  • 16. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W.
    J Clin Endocrinol Metab; 1989 Sep 15; 69(3):654-62. PubMed ID: 2668324
    [Abstract] [Full Text] [Related]

  • 17. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M.
    J Clin Invest; 1998 Apr 01; 101(7):1421-30. PubMed ID: 9525985
    [Abstract] [Full Text] [Related]

  • 18. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K.
    Diabetes; 1990 Nov 01; 39(11):1320-5. PubMed ID: 2146178
    [Abstract] [Full Text] [Related]

  • 19. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA.
    Am J Physiol Endocrinol Metab; 2004 Apr 01; 286(4):E621-5. PubMed ID: 14678954
    [Abstract] [Full Text] [Related]

  • 20. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.
    Diabetes; 2004 Mar 01; 53(3):654-62. PubMed ID: 14988249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.